Amyloid pathology associated with Alzheimer’s disease Alzheimer’s disease
Conditions
Interventions
Lumipulse G pTau 217/ß-Amyloid 1-42 Plasma Ratio
Sponsors
Bristol-Myers Squibb
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Subjects aged 55 years and over signs and symptoms of cognitive decline. Subjects (or their legally acceptable representative (LAR)) who have provided signed consent to participate in the performance evaluation study.None of the exclusion criteria apply.Additional inclusion criteria from clinical trials (CN0120023, CN0120024, CN0120056, CN0120051, CN0120052) may apply to the extent that they are investigated during the first screening visit.
Exclusion criteria
Exclusion criteria: Subjects under 55 years of ageAdditional exclusion criteria from clinical trials (CN0120023, CN0120024, CN0120056, CN0120051, CN0120052) may apply to the extent that they are investigated during the first screening visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study wants to evaluate what percentage of patients would deliver an indeterminate result across several clinical trials and would require further tests and evaluation for the confirmation of AD within the clinical trials | — |
Secondary
| Measure | Time frame |
|---|---|
| Not applicable. | — |
Countries
Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Romania, Serbia, Slovakia, South Korea, Spain, Taiwan, Turkey, Ukraine, United Kingdom, United States
Contacts
Public ContactHZ Zhao
Bristol-Myers Squibb
Outcome results
None listed